


RECEIVED

NOV 01 2002

Page 6 of 11

TECH CENTER 1600/2900


FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 20784/6		SERIAL NO. 10/082,001	
				APPLICANT(S): Demuth et al.			
				FILING DATE: February 22, 2002		ART UNIT: 1646 -1653	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
CMK	AA	2,961,377	11/22/1960	Shapiro et al.	167	65	
	AB	3,174,901	03/23/1965	Sterne	167	65	
	AC	3,879,541	04/22/1975	Kabbe et al.	424	326	
	AD	3,960,949	06/01/1976	Ahrens et al.	260	564 B	
	AE	4,028,402	06/07/1977	Fischer et al.	260	501.14	
	AF	4,935,493	06/19/1990	Bachovchin et al.	530	331	
	AG	5,433,955	07/18/1995	Bredehorst et al.	424	94.3	
	AH	5,462,928	10/31/1995	Bachovchin et al.	514	19	
	AI	5,512,549	4/30/1996	Chen et al.	514	12	
	AJ	5,543,396	08/06/1996	Powers et al.	514	19	
	AK	5,614,379	03/25/1997	MacKellar	435	68.1	
	AL	5,624,894	04/29/1997	Bodor	514	2	
	AM	5,939,560	08/17/1999	Jenkins et al.	548	535	
CMK	AN	6,006,753	12/28/1999	Efendic	128	898	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
CMK	BA	WO 01/62266 A2	08/30/2001	PCT	A61K	38/00	Y
	BB	WO 00/53171	09/14/2000	PCT	A61K	31/155	Y
	BC	DT 25 42 598 A1	04/22/1976	Germany	C07C	129/16	N
	BD	FR 2 696 740 A1	04/15/1994	France	C07D	207/404	N
	BE	FR 2 085 665	12/31/1971	France	A61K	27/00	N
CMK	BF	WO 97/40832	11/06/1997	PCT	A61K	31/425	Abstract only
Examiner: <i>CHL</i>				Date: <i>12/8/03</i>			



RECEIVED

NOV 01 2002 Page 7 of 11

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/6		SERIAL NO. 10/082,001			
APPLICANT(S): Demuth et al.				FILING DATE: February 22, 2002			
				ART UNIT: 1646			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
CMK	BG	WO 95/15309	06/08/1995	PCT	C07D	207/16	Y
	BH	JP 4334357	11/20/1992	Japan	C07C	233/57	Abstract only
	BI	WO 93/08259	04/29/1993	PCT	C12N		Y
	BJ	WO 95/11689	05/04/1995	PCT	A61K	37/00	Y
	BK	WO 97/45117	12/04/1997	PCT	A61K	31/435	Y
	BL	DE 196 16 486 C2	10/30/1997	Germany	A61K	45/00	Y
	BM	WO 95/29691	11/09/1995	PCT	A61K	38/00	Y
	BN	WO 98/22494	05/28/1998	PCT	E07K	5/06	Y
	BO	WO 00/01849	01/13/2000	PCT	G12Q	1/68	Y
	BP	EP 0 658 568 A1	06/21/1995	EPO	C07K	14/605	Y
CMK	BQ	DD 296 075 A5	11/21/1991	Germany	E07D	295/04	Y
	BR	DD 296 075 A5	11/21/1991	Germany	C07D	295/04	N
CMK	BS	EP 0 708 179 A2	04/24/1996	EPO	C12N	15/16	Y
	BT	EP 0 995 440 A1	04/26/2000	EPO	A61K	31/425	N
CMK	BU	WO 91/11457	08/08/1991	PCT	C07K	7/34	Y
	BV	WO 91/16339	10/31/1991	PCT	C07K	5/10	Y
	BW	WO 98/19998	05/14/1998	PCT	E07D	207/00	Y
	BX	WO 91/17767	11/28/1991	PCT	A61K	37/54	Y
	BY	JP 04-288098	10/13/1992	JP	A61K	37/64	(Abstract Only)
CMK	BZ	WO 99/46272 A	09/16/1999	PCT	C07F	9/572	Y
	BAA	DE 299 09 210 U	09/09/1999	Germany	A61K	31/425	N
Examiner: <i>CHL</i>				Date: <i>12/8/03</i>			




RECEIVED

NOV 01 2002

Page 8 of 11

CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/6	SERIAL NO. 10/082,001
		APPLICANT(S): Demuth et al.	
		FILING DATE: February 22, 2002	ART UNIT: 1646
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
CMK	CA	Campbell, I.W. <u>New Antidiabetic Drugs</u> , ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, "Sulphonylureas and metformin: efficacy and inadequacy". 3:33-51 (1990).	
	CB	The Merck Index, 11 th Edition, <u>An Encyclopedia of Chemicals, Drugs, and Biologicals</u> , 1989, Page 934	
	CC	The Merck Index, 12 th Edition, <u>An Encyclopedia of Chemicals, Drugs, and Biologicals</u> , 1996, Page 1014.	
	CD	<u>Martindale The Extra Pharmacopoeia</u> , 30 th Edition, London Pharmaceutical Press, 1993, Page 1619.	
	CE	<u>Martindale The Extra Pharmacopoeia</u> , 30 th Edition, London Pharmaceutical Press, 1993, Page 36.	
	CF	<u>CHEMICAL ABSTRACTS</u> , vol. 115, No. 15, 14. October 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN EKKEHARD ET AL: "Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes"	
	CG	<u>CHEMICAL ABSTRACTS</u> , vol. 126, no. 2, 13. January 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL A. ET AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides".	
	CH	<u>CHEMICAL ABSTRACTS</u> , vol. 118, no. 25, 21. June 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Hosoda, et al, "Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors", November 1992 (1992-11-20)	
	CI	ARAI ET AL., "Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain" <u>CHEMICAL AND PHARMACEUTICAL BULLETIN</u> , Bd. 41, No. 9, 1993, pages. 1583-1588.	
	CJ	J. Lin et al.: "Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics" <u>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA</u> , Vol. 95, November 1998, pages 14020-14024.	
	CK	KOROM, S., et al "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients", <u>Transplantation</u> , Vol. 63, 1495 - 1500 No. 10 (1997)	
	CL	TANKA, S., et al., "Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV". <u>Int. J. Immunopharmacol</u> , Vol. 19, No. 1 Pages 15-24, (1997)	
	CM	MENTLEIN, R., et al., "Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV". <u>Regul. Pept.</u> 49, 133 -144 (1993)	
	CN	WETZEL, W., et al., "Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes". <u>Neuropeptides</u> , 31, 41- 45 (1997)	
	CO	AMASHEH, S., et al., "Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in <i>Xenopus Laevis</i> oocytes". <u>J. Physiol.</u> 504, 169-174 (1997)	
CMK	CP	DURINX, C.; et al.; "Reference Values for Plasma Dipeptidyl-Peptidase IV activity and their Association with Other Laboratory Parameters". <u>Clin Chem Lab Med</u> 2001, February; 39 (2) :155-9, 1 page.	
Examiner:		Date: 12/8/03	



RECEIVED

NOV 01 2002

Page 9 of 11

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/6	SERIAL NO. 10/082,001
		APPLICANT(S): Demuth et al.	
		FILING DATE: February 22, 2002	ART UNIT: 1646
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
CMK	CQ	GOSSRAU, R.; "Cytochemistry of Membrane Proteases". <u>Histochem J</u> , 1985, July; 17 (7) :737-71, 1 page.	
	CR	HAHN, T.; et al.; "Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae". <u>Acta Histochem</u> 1993, December, 95 (2) :185-92, 1 page.	
	CS	HEYMANN, E. et al., "Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation." <u>Klin Wochenschr</u> , 1984, January, 2;62 (1) :2-10, 1 page.	
	CT	MAGYAR, C.E. et al., "Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension." <u>Am J. Physiol Renal Physiol</u> , 2000, August; 279 (2) :F358-69, 1 page.	
	CU	PAPIES, B. et al., "Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension." <u>Cor Vasa</u> , 1991; 33 (3) :218-26, 1 page.	
	CV	QURESHI, N.U.; et al., "Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock". <u>Regul Pept</u> , 1998, September 25; 75-76:215-20, 1 page.	
	CW	Index Nominum, <u>International Drug Directory 1992/1993</u> , Medpharm Scientific Publishers, pages 728-729.	
	CX	The Merck Index, <u>An Encyclopedia of Chemicals and Drugs</u> , 9 th Edition, Merck & Co., Inc., 1976, page 773	
	CY	Willms et al., <u>Journal of Clinical Endocrinology Metabolism</u> , "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients", 1996, 81(1): 327-332.	
	CZ	Hoffmann et al., <u>Journal of Chromatography A</u> , "Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary eletrophoresis", 1995, 716:355-362.	
	CAA	C.B. Welch, <u>Medical Management of Non-Insulin-Dependent (Type II) Diabetes</u> , 3 rd edition, American Diabetes Association, "Diagnosis and Classification" p. 3, 1994, Pharmacologic Intervention (2 pages).	
	CAB	Mannucci et al., <u>Diabetes Care</u> , "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects", 24(3): 489-494, March 2001.	
	CAC	Stryer, <u>Biochemistry 3rd Ed.</u> , "Protein Conformation, Dynamics, and Function", 1988, p 191-193.	
	CAD	Pauly et al., <u>Regulatory Peptides</u> , "Abstracts Issue: Abstracts from the 11 th International Symposium on Regulatory Peptides", July 15, 1996, 64(1-3): 148 plus cover.	
	CAE	Gutniak et al., <u>New England Journal of Medicine</u> , "Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients With Diabetes Mellitus", 1992, 326: 1316-1322.	
CMK	CAF	Hendrick et al., <u>Metabolism - Clinical and Experimental</u> , "Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats", January 1993, 42(1): 1-6.	
Examiner:		Date: 12/8/03	



RECEIVED


NOV 01 2002

Page 10 of 11

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY: DOCKET NO. 20784/6	SERIAL NO. 10/082,001
		APPLICANT(S): Demuth et al.	
		FILING DATE: February 22, 2002	ART UNIT: 1646
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
CMK	CAG	Nauck et al., <u>Diabetologia</u> , "Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients", (1993), 36: 741-744.	
	CAH	Gutniak et al., <u>Diabetes Care</u> , "Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM", September 1994, 17(9): 1039-1044.	
	CAI	Deacon et al., <u>Journal of Clinical Endocrinology and Metabolism</u> , "Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields and N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo", (1995), 80(3): 952-957.	
	CAJ	H.A. Smith et al., <u>Veterinary Pathology</u> (fourth edition), "Diseases and Disorders of Metabolism: Deficiency Diseases", (1972), p 1018-1020.	
	CAK	G.G. Duncan, <u>Diseases of Metabolism (Asian edition)</u> , "Diabetes Mellitus", (1966), p 951-957.	
	CAL	T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 In Vitro and In Vivo by DP IV", <u>Endocrinology</u> , Vol. 136(8), (1995), p 3585-3596.	
	CAM	C.F. Deacon et al., <u>Diabetes</u> , "Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded from the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects", September 1995, 44: 1126-1131.	
	CAN	Pauly et al., <u>Metabolism</u> , "Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-Thiazolidide", (1999), 48(3): 385-389.	
	CAO	<u>Vidal</u> , (1993), 69 th Edition, p. 612-613.	
	CAP	<u>Goodman & Gilman's The Pharmacological Basis of Therapeutics</u> , Ninth Edition, (1996), p. 1510.	
	CAQ	Nathan et al., <u>Diabetes Care</u> , "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects", February 1992, 15(2): 270-275.	
	CAR	<u>Psyhyrembel</u> , Kininisches Wörterbuch 257, Auflage, (1994), 9 pages.	
	CAS	Frohman et al., <u>Journal of Clin. Invest.</u> , "Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma in Vitro and in Vivo to a Biologically Inactive Product Cleaved at the NH ₂ Terminus", Volume 78, October 1986, p 906-913	
	CAT	Snow et al., <u>Advances In Medicinal Chemistry</u> , "Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents", Vol. 3, (1995), p 149-177.	
	CAU	Thorens et al., <u>Diabetes</u> , "Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM", (1993), 42:1219-1225.	
	CAV	Wakselman et al., "Inhibition of HIV-1 infection of CD 26 ⁺ but not CD 26 ⁻ cells by a potent cyclopeptidic inhibitor of the DPP IV activity of CD26", Abstract P 44 of the 24 th <u>European Peptide Symposium</u> , (1996).	
CMK	CAW	Ashworth et al., <u>BIOORG. MED. CHEM. LETT.</u> , "2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", (1996), 6(10): 1163-1166.	
Examiner:		Date: 12/8/03	



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/6	SERIAL NO. 10/082,001
		APPLICANT(S): Demuth et al.	
		FILING DATE: February 22, 2002	ART UNIT: 1646
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
CMK	CAX	Endroczi et al., <u>ACTA PHYSIOL. HUNG.</u> , "Dipeptidyl peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and Zn ²⁺ in Vitro", (1990), 75(1): 35-44.	
	CAY	Lee, H.S. et al., "Cathepsin B Inhibitory Peptides Derived from β -Casein," <u>Peptides</u> 21 (2000) 807-809.	
	CAZ	Edwards, J.V. et al., <u>J. Peptide Res.</u> , "Synthesis and Activity of NH ₂ - and COOH-Terminal Elastase Recognition Sequences on Cotton," (1999), 54: 536-543.	
	CBA	Wettstein, J.G. et al. <u>Pharmacology & Therapeutics</u> , "Central Nervous System Pharmacology of Neuropeptide Y.", (1995), 65(3): 397-414.	
	CBB	Badia-Elder N.E. et al., <u>Alcoholism Clinical and Experimental Research</u> , "Effects of Neuropeptide Y (NPY) on Ethanol Intake and Anxiety in High and Low Alcohol Drinking (HAD1/LAD1) Rats", (2000), 24(5): 82A.	
CMK	CBC	Munglani R. et al., <u>Drugs, Adis International Ltd, At</u> , "The Therapeutic Potential of Neuropeptide Y Analgesic, Anxiolytic and Antihypertensive", (1996) 52(3): 371-389.	
Examiner:  Date: 12/8/03			

RECEIVED

NOV 01 2002

TECH CENTER 1600/2900